In a challenging market environment, Ideaya Biosciences Inc . (NASDAQ:) stock has reached its 52-week low,…
Tag: IDEAYA
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug…